APA

Sieper J., Lenaerts J., Wollenhaupt J., Rudwaleit M., Mazurov V. I., Myasoutova L., Park S., Song Y., Yao R., Chitkara D. & Vastesaeger N. (20140211). Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. : Annals of the rheumatic diseases.

Chicago

Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov V I, Myasoutova L, Park S, Song Y, Yao R, Chitkara D and Vastesaeger N. 20140211. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. : Annals of the rheumatic diseases.

Harvard

Sieper J., Lenaerts J., Wollenhaupt J., Rudwaleit M., Mazurov V. I., Myasoutova L., Park S., Song Y., Yao R., Chitkara D. and Vastesaeger N. (20140211). Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. : Annals of the rheumatic diseases.

MLA

Sieper J, Lenaerts J, Wollenhaupt J, Rudwaleit M, Mazurov V I, Myasoutova L, Park S, Song Y, Yao R, Chitkara D and Vastesaeger N. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. : Annals of the rheumatic diseases. 20140211.